X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6921) 6921
Magazine Article (19) 19
Book Chapter (6) 6
Conference Proceeding (3) 3
Government Document (2) 2
Book Review (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5866) 5866
male (3883) 3883
female (3488) 3488
piperidines - adverse effects (3181) 3181
piperidines - therapeutic use (3175) 3175
middle aged (2396) 2396
adult (2280) 2280
aged (1867) 1867
piperidines - administration & dosage (1808) 1808
piperidines - pharmacology (1705) 1705
animals (1573) 1573
pharmacology & pharmacy (1281) 1281
double-blind method (1070) 1070
treatment outcome (1003) 1003
dose-response relationship, drug (845) 845
anesthesiology (772) 772
remifentanil (715) 715
rats (675) 675
double-blind (606) 606
adolescent (604) 604
psychiatry (588) 588
indans - therapeutic use (584) 584
neurosciences (569) 569
time factors (560) 560
piperidines - pharmacokinetics (558) 558
mice (523) 523
donepezil (511) 511
aged, 80 and over (505) 505
clinical neurology (500) 500
alzheimer disease - drug therapy (486) 486
clinical trials as topic (468) 468
drug therapy (460) 460
efficacy (453) 453
pharmacokinetics (450) 450
anesthesia (436) 436
cholinesterase inhibitors - therapeutic use (433) 433
prospective studies (429) 429
indans - adverse effects (423) 423
drug therapy, combination (414) 414
medicine & public health (406) 406
propofol (400) 400
young adult (399) 399
surgery (372) 372
analysis (371) 371
medicine, general & internal (369) 369
oncology (364) 364
safety (361) 361
research (354) 354
care and treatment (346) 346
administration, oral (343) 343
alzheimer's disease (340) 340
piperidines (339) 339
cholinesterase inhibitors - adverse effects (320) 320
clinical trials (316) 316
pyrazoles - pharmacology (316) 316
analgesics, opioid - adverse effects (311) 311
dementia (307) 307
drug interactions (307) 307
drug administration schedule (305) 305
abridged index medicus (298) 298
blood pressure - drug effects (295) 295
anesthetics, intravenous - adverse effects (285) 285
randomized controlled trials as topic (279) 279
child (276) 276
rats, sprague-dawley (270) 270
heart rate - drug effects (269) 269
schizophrenia - drug therapy (269) 269
disease models, animal (265) 265
health aspects (263) 263
pain (263) 263
risk factors (262) 262
pyrazoles - therapeutic use (260) 260
dosage and administration (255) 255
analgesics, opioid - administration & dosage (254) 254
anesthetics, intravenous - administration & dosage (248) 248
diabetes mellitus, type 2 - drug therapy (248) 248
pharmacology/toxicology (240) 240
pyrimidines - therapeutic use (238) 238
therapy (237) 237
pharmacology (236) 236
receptor, cannabinoid, cb1 - antagonists & inhibitors (235) 235
antipsychotic agents - adverse effects (234) 234
internal medicine (226) 226
alzheimers-disease (218) 218
cancer (218) 218
endocrinology & metabolism (218) 218
nootropic agents - therapeutic use (218) 218
antipsychotic agents - therapeutic use (216) 216
fentanyl (214) 214
drugs (213) 213
pyrroles - therapeutic use (212) 212
propofol - administration & dosage (210) 210
rivastigmine (204) 204
follow-up studies (202) 202
infusions, intravenous (201) 201
geriatrics & gerontology (197) 197
research article (196) 196
cross-over studies (193) 193
protein kinase inhibitors - therapeutic use (193) 193
placebo (192) 192
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6400) 6400
French (164) 164
German (144) 144
Japanese (96) 96
Spanish (71) 71
Chinese (30) 30
Italian (24) 24
Russian (22) 22
Danish (17) 17
Dutch (14) 14
Polish (10) 10
Portuguese (10) 10
Norwegian (8) 8
Hungarian (6) 6
Swedish (5) 5
Finnish (2) 2
Turkish (2) 2
Afrikaans (1) 1
Bulgarian (1) 1
Croatian (1) 1
Czech (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The oncologist (Dayton, Ohio), ISSN 1549-490X, 2017, Volume 22, Issue 7, pp. 823 - 833
Tremendous progress has been made in the clinical landscape of advanced‐stage BRAF V600–mutant melanoma treatment over the past 5 years. Targeted therapies... 
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | IMPROVED SURVIVAL | PHASE-3 | COMBINATION | COMBINED DABRAFENIB | THERAPY | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | COBIMETINIB | BRAF-MUTANT MELANOMA | VEMURAFENIB | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma and Cutaneous Malignancies
Journal Article
Rheumatology (Oxford, England), ISSN 1462-0332, 2016, Volume 56, Issue 3, pp. kew442 - 425
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2014, Volume 71, Issue 6, pp. 1102 - 1109.e1
Background BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) frequently cause cutaneous adverse events... 
Dermatology | cutaneous adverse event | rash | histology | inflammation | therapy | squamous cell carcinoma | squamous cell carcinoma therapy | ACTIVATION | IMPROVED SURVIVAL | OPEN-LABEL | DERMATOLOGY | METASTATIC MELANOMA | MEK INHIBITION | PATHWAY | RESISTANCE | RAF INHIBITORS | MUTATIONS | VEMURAFENIB | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Skin Neoplasms - drug therapy | Follow-Up Studies | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Young Adult | Pyridones - administration & dosage | Carcinoma, Squamous Cell - mortality | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Retrospective Studies | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Kaplan-Meier Estimate | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Azetidines - administration & dosage | Carcinoma, Squamous Cell - drug therapy | Indoles - adverse effects | Melanoma - drug therapy | Piperidines - adverse effects | Adolescent | Sulfonamides - adverse effects | Aged | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma - mortality | Complications and side effects | Medical colleges | Melanoma
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2017, Volume 76, Issue 4, pp. 736 - 744
New molecularly targeted therapeutics are changing dermatologic therapy. Janus kinase–signal transducer and activator of transcription (JAK-STAT) is an... 
Dermatology | JAK-STAT | psoriasis | baricitinib | vitiligo | atopic dermatitis | JAK inhibitor | ruxolitinib | alopecia areata | tofacitinib | RHEUMATOID-ARTHRITIS | OCLACITINIB APOQUEL(R) | OPEN-LABEL | DERMATOLOGY | LONG-TERM EXTENSION | PHASE 2B TRIAL | ALOPECIA-AREATA | ATOPIC-DERMATITIS | JANUS KINASE INHIBITOR | PLAQUE PSORIASIS | TOFACITINIB CITRATE | Pyrazoles - therapeutic use | Dermatitis, Atopic - enzymology | Humans | Dermatologic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Dermatologic Agents - adverse effects | Anti-Inflammatory Agents - adverse effects | Anti-Inflammatory Agents - therapeutic use | Pyrroles - adverse effects | Vitiligo - drug therapy | Pyrroles - therapeutic use | Pyrazoles - adverse effects | Psoriasis - drug therapy | Vitiligo - enzymology | Azetidines - adverse effects | Alopecia Areata - enzymology | Skin Diseases - drug therapy | Clinical Trials as Topic | Dermatologic Agents - classification | Janus Kinases - antagonists & inhibitors | Dermatitis, Atopic - drug therapy | Alopecia Areata - drug therapy | Azetidines - therapeutic use | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Psoriasis - enzymology | Skin Diseases - enzymology | Medical colleges | Psoriasis | Atopic dermatitis | Formulae, receipts, prescriptions | Dermatologic agents | Pharmaceutical industry | Tyrosine | Interleukins | Interferon | Biological response modifiers | T cells | Tofacitinib
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 04/2018, Volume 2018, Issue 4, pp. CD011746 - CD011746
Background Biliary tract cancers are a group of rare heterogeneous malignant tumours. They include intrahepatic and extrahepatic cholangiocarcinomas,... 
Medical interventions | MALIGNANT CHOLANGIOCARCINOMA INCLUDING PERIAMPULLAR CANCER (C24.1) (M8160/3) | Capecitabine | Organoplatinum Compounds | Tegafur | Gemcitabine‐based therapy | Biliary Tract Neoplasms | Gallbladder & bile duct disease | Quinazolines | Ampulla of Vater | MALIGNANT COMBINED HEPATO‐CELLULAR CHOLANGIOCARCINOMA (C22.0) (M8180/3) | Oxaliplatin | Oxonic Acid | Piperidines | Cholangiocarcinoma | Medical intervention | Chemotherapeutic agents | Mitomycin | Gastroenterology & hepatology | Antineoplastic Combined Chemotherapy Protocols | Cisplatin | Gallbladder cancer | Randomized Controlled Trials as Topic | Treatment | Deoxycytidine | Gallbladder Neoplasms | Antimetabolites, Antineoplastic | Other types of cancer | Medicine General & Introductory Medical Sciences | Drug Combinations | Cancer | MEDICINE, GENERAL & INTERNAL | INTRAHEPATIC CHOLANGIOCARCINOMA | RISK-FACTORS | RANDOMIZED PHASE-II | DESIGN CHARACTERISTICS | FINDINGS TABLES | EMPIRICAL-EVIDENCE | GALLBLADDER CANCER | POOLED ANALYSIS | SINGLE-AGENT GEMCITABINE | TRIAL SEQUENTIAL-ANALYSIS | Capecitabine - administration & dosage | Gallbladder Neoplasms - mortality | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Biliary Tract Neoplasms - mortality | Cisplatin - administration & dosage | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Deoxycytidine - adverse effects | Female | Quinazolines - administration & dosage | Biliary Tract Neoplasms - drug therapy | Biliary Tract Neoplasms - pathology | Mitomycin - adverse effects | Piperidines - administration & dosage | Tegafur - adverse effects | Cholangiocarcinoma - mortality | Oxonic Acid - administration & dosage | Oxonic Acid - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Cholangiocarcinoma - pathology | Gallbladder Neoplasms - drug therapy | Capecitabine - adverse effects | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Piperidines - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Quinazolines - adverse effects | Cisplatin - adverse effects | Tegafur - administration & dosage | Gallbladder Neoplasms - pathology | Mitomycin - administration & dosage | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2017, Volume 76, Issue 4, pp. 745 - 753.e19
.... Methods This is a systematic review of PubMed and ClinicalTrials.gov. Results One hundred thirty-four articles matched our search terms, of which 78 were original articles and 12 reports on adverse events... 
Dermatology | dermatology | psoriasis | baricitinib | vitiligo | atopic dermatitis | ruxolitinib | alopecia areata | JAK inhibitors | graft versus host disease | tofacitinib | CONSTITUTIVE ACTIVATION | LUPUS-ERYTHEMATOSUS | T-CELL LYMPHOMA | VERSUS-HOST-DISEASE | LONG-TERM EXTENSION | ALOPECIA-AREATA | JAK1/2 INHIBITOR | CHRONIC PLAQUE PSORIASIS | RANDOMIZED PHASE-III | TOFACITINIB CITRATE | Pyrazoles - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Dermatologic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Dermatologic Agents - adverse effects | Anti-Inflammatory Agents - adverse effects | Antineoplastic Agents - adverse effects | Anti-Inflammatory Agents - therapeutic use | Pyrroles - adverse effects | Pyrroles - therapeutic use | Pyrazoles - adverse effects | Drug Eruptions - etiology | Psoriasis - drug therapy | Azetidines - adverse effects | Alopecia Areata - enzymology | Skin Diseases - drug therapy | Randomized Controlled Trials as Topic | Janus Kinases - antagonists & inhibitors | Alopecia Areata - drug therapy | Azetidines - therapeutic use | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Psoriasis - enzymology | Skin Diseases - enzymology | Mutual fund industry | Lupus | Psoriasis | Dermatologic agents | Arthritis | Non-Hodgkin's lymphomas | T cells | Rheumatoid factor | Atopic dermatitis | Analysis | Formulae, receipts, prescriptions | Respiratory tract diseases | Skin
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 9, pp. 829 - 838
... with a 50% maximum inhibitory concentration of 1.9 nmol per liter in enzymatic analyses and with activity against the effects of several ALK mutations that confer... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article